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Introduction
============

Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, accounting for over 17 million deaths each year^[@bib1])^. By 2030, almost 23.6 million people will die from CVD, mainly from coronary heart disease (CHD), which is the major manifestation of CVD^[@bib2])^. Coronary heart disease, considered to be a manifestation of a chronic inflammatory response to injury or infection, is characterized by focal lipidrich deposits called atheroma, which is initiated by the process of atherosclerosis^[@bib3])^. Endothelial dysfunction is known to play a pivotal role in the development of atherosclerosis. Endothelial cells play an important role in the regulation of homeostasis, arterial wall structure and tension, and undisturbed blood flow^[@bib4])^. Soluble cell adhesion molecules \[such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin\], which are glycoproteins integral to the cell membrane, are responsible for the adhesion of different cells onto the endothelial surface^[@bib5])^. Cell adhesion molecules facilitate the attachment of circulating leucocytes to the endothelium, to sites of inflammation, and their subsequent movement and accumulation in arterial walls^[@bib6]--[@bib9])^, all of which are processes pivotal in the development and progression of atherosclerosis^[@bib10])^. E-selectin and P-selectin mediate transient rolling of leucocytes along the endothelium^[@bib11])^, whiles VCAM-1 and ICAM-1 mediate stronger attachment of leucocytes to the endothelium^[@bib9])^. Circulating levels of these cell adhesion molecules (including VCAM-1) are associated with several cardiovascular risk factors and markers^[@bib12])^ and higher levels have been detected in atherosclerotic lesions^[@bib13],\ [@bib14])^ and in patients with ischemic stroke, coronary artery disease, and CVD^[@bib15]--[@bib18])^.

Emerging evidence indicates that these soluble cell adhesion molecules may be linked to the future risk of CVD. A number of prospective studies, based in general population settings, have generally reported positive and independent associations between CVD outcomes and circulating levels of E-selectin, P-selectin, or ICAM-1^[@bib16],\ [@bib19]--[@bib24])^; however, the association of VCAM-1 with CVD is unclear as previous studies have mostly reported null associations between VCAM-1 and CVD outcomes^[@bib21],\ [@bib23],\ [@bib25])^. A single study demonstrated an increased risk of cardiovascular mortality with increased levels of VCAM-1, but the association was particularly evident among subjects with a history of type 2 diabetes^[@bib26])^. Given the uncertainty in the existing evidence, our primary objective was to characterize the shape and assess the magnitude and independence of the prospective association between VCAM-1 concentrations and CVD risk using a population-based sample of 2,638 participants free from pre-existing CVD at baseline. A secondary objective was to investigate the extent to which VCAM-1 concentrations could improve the prediction of first-onset CVD when added to a conventional CVD risk prediction model.

Materials and Methods
=====================

This report was conducted according to STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines for reporting observational studies in epidemiology (**[Appendix 1](#T5){ref-type="table"}**)^[@bib27])^.

###### STROBE 2007 Statement---Checklist of items that should be included in reports of cohort studies

  Section/Topic              Item^\#^                                                                                                Recommendation                                                                                                                                                                                                   Reported on page^\#^
  -------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  Title and abstract         1                                                                                                       \(a\) Indicate the study\'s design with a commonly used term in the title or the abstract                                                                                                                        Page 804
                             \(b\) Provide in the abstract an informative and balanced summary of what was done and what was found   Page 804                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                      
  Introduction                                                                                                                                                                                                                                                                                                                                        
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  Study design               4                                                                                                       Present key elements of study design early in the paper                                                                                                                                                          Study Design and Participants
  Setting                    5                                                                                                       Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection                                                                                  Study Design and Participants
  Participants               6                                                                                                       \(a\) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up                                                                                     Study Design and Participants
                                                                                                                                     \(b\) For matched studies, give matching criteria and number of exposed and unexposed                                                                                                                            Not applicable
  Variables                  7                                                                                                       Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                                         Risk Factor Assessment
  Data sources/measurement   8\*                                                                                                     For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group                             Risk Factor Assessment
  Bias                       9                                                                                                       Describe any efforts to address potential sources of bias                                                                                                                                                        Statistical Analyses
  Study size                 10                                                                                                      Explain how the study size was arrived at                                                                                                                                                                        Statistical Analyses
  Quantitative variables     11                                                                                                      Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why                                                                                     Statistical Analyses
  Statistical methods        12                                                                                                      \(a\) Describe all statistical methods, including those used to control for confounding                                                                                                                          Statistical Analyses
                                                                                                                                     \(b\) Describe any methods used to examine subgroups and interactions                                                                                                                                            Statistical Analyses
                                                                                                                                     \(c\) Explain how missing data were addressed                                                                                                                                                                    Not applicable
                                                                                                                                     \(d\) If applicable, explain how loss to follow-up was addressed                                                                                                                                                 Not applicable
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                                                                                                                                     \(c\) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period                                                                                               
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  Funding                    22                                                                                                      Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                                                    Page 816

Study Design and Participants
-----------------------------

The study population, consisting of a representative sample of inhabitants living in the city of Groningen in the Netherlands, were participants in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study, a longitudinal general population-based study designed to investigate the natural course of urinary albumin excretion and its relationship to renal disease and CVD. The actual PREVEND cohort (*N* = 8,592) was recruited from inhabitants aged 28--75 years invited for pre-screening from the city of Groningen in the Netherlands. Baseline examinations and measurements were performed between 1997 and 1998. Participants with a prevalent history of CVD, liver disease, renal disease, or malignancy were excluded in the present analysis. Given that assays for VCAM-1 could only be measured in a random subset of PREVEND participants because of financial constraints, our final cohort for this analysis included 2,638 participants with complete information on serum VCAM-1, relevant covariates, and cardiovascular outcomes. Participants in the PREVEND study included men and women recruited from an ethnically homogeneous population, and therefore characteristics of excluded participants were generally not different from those included in the final analyses (**[Appendix 2](#T6){ref-type="table"}**). The derivation of the analytic sample is reported in **[Appendix 3](#F3){ref-type="fig"}**. The medical ethics committee of the University Medical Center Groningen duly approved the PREVEND study, which was conducted in accordance with the Declaration of Helsinki. Each participant provided written informed consent for voluntary participation, which was documented in a consent form approved by the medical ethics committee.

###### Baseline characteristics of participants with and without VCAM-1 measurements

                                                        With VCAM-1 measurements Mean (SD) median (IQR) or %   Without VCAM-1 measurements Mean (SD) or median (IQR) or %
  ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------
  Questionnaire                                                                                                
    Male                                                49.1                                                   47.7
    Age at survey (years)                               51 (13)                                                47 (12)
    History of diabetes                                 4.1                                                    2.9
    Smoking                                                                                                    
      Current                                           33.7                                                   33.7
      Former                                            36.5                                                   34.9
      Never                                             29.8                                                   31.4
    Alcohol consumers                                   74.8                                                   75.9
    History of hypertension                             12.1                                                   8.8
    Regular use of anti-hypertensive medication         13.7                                                   9.4
    Regular use of lipid-lowering medication            3.3                                                    2.0
  Physical measurements                                                                                        
    BMI (kg/m^2^)                                       26.2 (4.2)                                             25.9 (4.3)
    WHR                                                 0.88 (0.09)                                            0.87 (0.09)
    SBP (mmHg)                                          130 (21)                                               127 (19)
    DBP (mmHg)                                          75 (10)                                                73 (10)
  Lipid markers                                                                                                
    Total cholesterol (mmol/l)                          5.72 (1.14)                                            5.58 (1.11)
    HDL-C (mmol/l)                                      1.34 (0.41)                                            1.33 (0.40)
    Triglycerides (mmol/l)                              1.16 (0.85--1.69)                                      1.12 (0.82--1.64)
  Metabolic, inflammatory, and renal function markers                                                          
    hsCRP (mg/l)                                        1.34 (0.57--3.06)                                      1.14 (0.50--2.72)
    Fasting plasma glucose (mmol/l)                     4.85 (1.23)                                            4.82 (1.03)
    Creatinine (µmol/l)                                 82 (74--92)                                            82 (73--91)
    Cystatine C (mg/dl)                                 0.82 (0.24)                                            0.78 (0.17)
    eGFR (ml/min/1.73 m^2^)                             92.6 (20.0)                                            97.1 (19.1)
    UAE (mg/24 hours)                                   8.04 (5.77--14.38)                                     9.88 (6.63--18.01)

BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; ; hsCRP, high sensitivity C-reactive protein; IQR, interquartile range; SBP, systolic blood pressure; UAE, urinary albumin excretion; VCAM-1, vascular cell adhesion molecule-1; WHR, waist-to-hip ratio

![Derivation of the analytic sample\
CVD, cardiovascular disease; VCAM-1, vascular cell adhesion molecule-1](jat-24-804-g003){#F3}

Risk Factor Assessment
----------------------

During two outpatient visits by study participants, baseline data on sociodemographics, medical history, physical health, including anthropometric measurements, and risk markers for CVD were assessed. Blood biomarker analyses were performed on plasma and serum venous samples taken from participants after an overnight fast and 15 minutes of rest. Concentrations of VCAM-1 were determined in ethylenediaminetetraacetic acid (EDTA) plasma (that had been stored frozen at −80°C for 15 years) using the sandwich enzyme-linked immunosorbent assay (Diaclone human sVCAM-1/CD106 ELISA, Diaclone SAS, France) with the minimal detection limit being 0.6 ng/ml. The inter-assay coefficients of variation were 5.94% and 1.44% in the lower normal and higher normal range, respectively. Plasma glucose was measured by dry chemistry (Eastman Kodak, Rochester, New York). Total cholesterol, high-density lipoprotein cholesterol (HDL-C), high sensitivity C-reactive protein (hsCRP), triglycerides, serum creatinine, and serum cystatin C were measured using standard laboratory methods, which have been described previously^[@bib28]--[@bib32])^. Urinary albumin excretion (UAE) was calculated as the mean of two 24-hour urine collections. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) combined creatinine-cystatin C equation^[@bib33])^. Type 2 diabetes mellitus and hypertension were defined as previously reported^[@bib31],\ [@bib32],\ [@bib34])^.

Outcome Assessment for CVD
--------------------------

The primary endpoint in our study was firstonset CVD, with incident CHD and stroke as secondary endpoints. Ascertainment of dates and causes of death were by record linkage with the Dutch Central Bureau of Statistics. Information on hospitalization for cardiovascular morbidity was retrieved from PRISMANT, the Dutch national registry of hospital discharge diagnoses^[@bib35])^. All data were coded according to the *International Classification of Diseases*, Ninth Revision (ICD-9) until 01-01-2009. The data were coded according to ICD-10 codes after this date. First-onset CVD was defined as the combined endpoint of acute myocardial infarction, acute and subacute ischemic heart disease, coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, subarachnoid hemorrhage, intracerebral hemorrhage, other intracranial hemorrhage, occlusion or stenosis of the precerebral or cerebral arteries, and other vascular interventions, such as percutaneous transluminal angioplasty or bypass grafting of peripheral vessels and aorta. Coronary heart disease events were defined as fatal or nonfatal myocardial infarction (MI), fatal or nonfatal ischemic heart disease (IHD), coronary artery bypass grafting (CABG), and percutaneous transluminal coronary angioplasty (PTCA). Stroke events were defined as subarachnoid hemorrhage, intracerebral hemorrhage, other and unspecified intracranial hemorrhage, occlusion and stenosis of precerebral or cerebral arteries, and carotid obstruction. Further details on the definition of cardiovascular outcomes are provided in previous reports^[@bib34],\ [@bib36])^.

Statistical Analyses
--------------------

Skewed variables (e.g., VCAM-1, hsCRP, triglycerides, creatinine, and UAE) were natural logarithm (log~e~) transformed to achieve approximately normal distributions. Descriptive analyses were performed to summarize baseline characteristics of participants. The standard deviation (SD) of baseline log VCAM-1 concentration was 0.45, corresponding to approximately 1.6-fold higher circulating VCAM-1 (i.e., e^0.45^ = 1.57). The cross-sectional associations of serum VCAM-1 with CVD risk markers were assessed by calculating Pearson\'s correlation coefficients adjusted for age and sex. Analyses of the associations between serum VCAM-1 concentrations and risk of cardiovascular outcomes involved time-to-event Cox proportional hazards models after confirmation of assumptions of proportionality of hazards^[@bib37])^. Collinearity diagnostics using the variance inflation factor^[@bib38])^ showed no evidence of collinearity among covariates, including between UAE and eGFR. To characterize the shape of the association, hazard ratios (HRs) estimated within quintiles of baseline VCAM-1 concentrations relative to the bottom quintile were plotted against mean log~e~ VCAM-1 levels in each quintile using floating absolute risks (FARs)^[@bib39])^ as described in detail previously^[@bib40],\ [@bib41])^. Vascular cell adhesion molecule-1 was modeled as both continuous (per 1 SD) higher log~e~ serum VCAM-1 levels) and categorical (quintiles defined according to the baseline distribution of serum VCAM-1 level) variables. To assess the independence of the association, HRs were calculated with progressive adjustment for age and sex, other established CVD risk factors (smoking status, history of diabetes, SBP, total cholesterol, and HDL-C), potential confounders \[body mass index (BMI), alcohol consumption, fasting glucose, triglycerides, eGFR, and hsCRP\], and UAE. Effect modification by individual characteristics, such as age, sex, and other cardiovascular risk markers, were assessed using interaction tests. To limit potential biases due to reverse causation, we carried out subsidiary analyses that excluded the first two years of follow-up, participants on regular antihypertensive medication, and participants on regular lipid-lowering medication (statins).

To assess whether adding information on VCAM-1 to a model that included conventional cardiovascular risk factors^[@bib42])^ is associated with improvement in CVD risk prediction, we calculated measures of discrimination for censored time-to-event data (Harrell\'s C-index^[@bib43])^) and reclassification. To investigate the change in C-index, we added VCAM-1 to a model based on risk factors included in the Framingham CVD Risk Score (i.e., age, sex, smoking status, SBP, total cholesterol, and HDL-C)^[@bib44])^. For participants with at least 10 years of follow-up, reclassification of participants was assessed using the net-reclassification-improvement (NRI)^[@bib45])^ across predicted 10-year cardiovascular risk categories of low (\< 5%), intermediate (5 to \< 7.5%), and high (≥ 7.5%) risk^[@bib46])^. Risk prediction analysis was restricted to participants without a known history of diabetes or CVD at baseline. All statistical analyses were conducted using Stata version 14 (Stata Corp, College Station, Texas).

Results
=======

Baseline Characteristics and Correlates of VCAM-1
-------------------------------------------------

Data were available for 2,638 participants without a known history of CVD at baseline. The mean age of overall participants at baseline was 51 (SD 13) years, and 49% were males (**[Table 1](#T1){ref-type="table"}**). The mean (SD) log~e~ VCAM-1 was 6.79 (0.45) ng/ml. Except for VCAM-1 levels, there were significant differences in clinically relevant subgroups and levels of risk markers between participants who did and did not develop CVD. Log~e~ VCAM-1 levels were weakly correlated with risk markers for CVD. Baseline VCAM-1 concentrations were higher by 7% in men compared with women, by 17% in people with diabetes compared with people without diabetes, and by 6% in people with a history of hypertension compared with those without a history. The levels were lower by 6% in current and former smokers compared with non-smokers and by 6% in current alcohol consumers compared with non-consumers (**[Table 2](#T2){ref-type="table"}**).

###### Baseline participant characteristics overall and according to the development of incident cardiovascular disease

                                                        Overall (*N* = 2,638) Mean (SD) or median (IQR) or n (%)   Without incident CVD (*N* = 2,024) Mean (SD) median (IQR) or n (%)   With incident CVD (*N* = 614) Mean (SD) or median (IQR) or n (%)   *P*-value
  ----------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------ -----------
  VCAM-1 (ng/ml)                                        911.0 (651.9--1,231.3)                                     901.1 (647.6--1,220.3)                                               940.3 (664.3--1,261.5)                                             0.183
  Questionnaire                                                                                                                                                                                                                                            
    Male                                                1,288 (48.8)                                               869 (42.9)                                                           419 (68.2)                                                         \< 0.001
    Age at survey (years)                               51 (13)                                                    48 (12)                                                              60 (11)                                                            \< 0.001
    History of diabetes                                 101 (3.8)                                                  46 (2.3)                                                             55 (9.0)                                                           \< 0.001
    Smoking                                                                                                                                                                                                                                                
      Current                                           887 (33.6)                                                 622 (30.7)                                                           265 (43.2)                                                         
      Former                                            967 (36.7)                                                 731 (36.1)                                                           236 (38.4)                                                         \< 0.001
      Never                                             784 (29.7)                                                 671 (33.2)                                                           113 (18.4)                                                         
    Alcohol consumers                                   1,970 (74.7)                                               1,540 (76.1)                                                         430 (70.0)                                                         0.003
    History of hypertension                             325 (12.3)                                                 170 (8.4)                                                            155 (25.2)                                                         \< 0.001
    Regular use of anti-hypertensive medication         357 (13.5)                                                 194 (9.6)                                                            163 (26.6)                                                         \< 0.001
    Regular use of lipid-lowering medication            88 (3.3)                                                   45 (2.2)                                                             43 (7.0)                                                           \< 0.001
  Physical measurements                                                                                                                                                                                                                                    
    BMI (kg/m^2^)                                       26.1 (4.2)                                                 25.8 (4.1)                                                           27.3 (4.0)                                                         \< 0.0001
    WHR                                                 0.88 (0.09)                                                0.87 (0.09)                                                          0.93 (0.09)                                                        \< 0.0001
    SBP (mmHg)                                          130 (21)                                                   126 (18)                                                             145 (23)                                                           \< 0.0001
    DBP (mmHg)                                          74 (10)                                                    73 (9)                                                               80 (10)                                                            \< 0.0001
  Lipid markers                                                                                                                                                                                                                                            
    Total cholesterol (mmol/l)                          5.72 (1.15)                                                5.60 (1.15)                                                          6.11 (1.08)                                                        \< 0.0001
    HDL-C (mmol/l)                                      1.34 (0.41)                                                1.39 (0.41)                                                          1.20 (0.39)                                                        \< 0.0001
    Triglycerides (mmol/l)                              1.16 (0.85--1.69)                                          1.11 (0.81--1.61)                                                    1.40 (0.99--2.03)                                                  \< 0.0001
  Metabolic, inflammatory, and renal function markers                                                                                                                                                                                                      
    hsCRP (mg/l)                                        1.34 (0.57--3.08)                                          1.14 (0.51--2.68)                                                    2.26 (1.07--4.97)                                                  \< 0.0001
    Fasting plasma glucose (mmol/l)                     4.82 (1.20)                                                4.69 (0.96)                                                          5.26 (1.72)                                                        \< 0.0001
    Creatinine (µmol/l)                                 82 (74--92)                                                81 (73--90)                                                          89 (78--99)                                                        \< 0.0001
    Cystatine C (mg/dl)                                 0.82 (0.23)                                                0.79 (0.21)                                                          0.90 (0.28)                                                        \< 0.0001
    eGFR (ml/min/1.73 m^2^)                             92.6 (20.0)                                                95.2 (19.6)                                                          83.9 (19.1)                                                        \< 0.0001
    UAE (mg/24 hours)                                   8.05 (5.80--14.38)                                         7.20 (5.49--11.02)                                                   14.65 (8.13--38.88)                                                \< 0.0001

BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; IQR, interquartile range; SBP, systolic blood pressure; UAE, urinary albumin excretion; VCAM-1, vascular cell adhesion molecule-1; WHR, waist-to-hip ratio

###### Cross-sectional correlates of VCAM-1

                                                              Pearson correlation r (95% CI)^[†](#tf4){ref-type="table-fn"}^   Percentage difference (95% CI) in VCAM-1 levels per 1 SD higher or compared to reference category of correlate^[‡](#tf5){ref-type="table-fn"}^
  ----------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Loge VCAM-1 (ng/ml)                                         \-                                                               \-
  ***Questionnaire***                                                                                                          
  Sex                                                                                                                          
    Female                                                    \-                                                               Ref
    Male                                                      \-                                                               7% (4, 11)[\*\*\*](#tf3){ref-type="table-fn"}
  Age at survey (years)                                       0.10 (0.06, 0.13)[\*\*\*](#tf3){ref-type="table-fn"}             4% (3, 6)[\*\*\*](#tf3){ref-type="table-fn"}
  History of diabetes                                                                                                          
    No                                                                                                                         
    Yes                                                                                                                        17% (7, 29)[\*\*](#tf2){ref-type="table-fn"}
  Smoking status                                                                                                               
    Non-smokers                                               \-                                                               Ref
    Current and former smokers                                \-                                                               −6% (−10, −3)[\*\*](#tf2){ref-type="table-fn"}
  Alcohol consumption                                                                                                          
    Non-consumers                                             \-                                                               Ref
    Current consumers                                         \-                                                               −6% (−10, −2)[\*\*](#tf1){ref-type="table-fn"}
  History of hypertension                                                                                                      
    No                                                        \-                                                               Ref
    Yes                                                       \-                                                               6% (1, 12)[\*](#tf1){ref-type="table-fn"}
  Regular use of anti-hypertensive medication                                                                                  
    No                                                        \-                                                               Ref
    Yes                                                       \-                                                               7% (2, 13)[\*](#tf1){ref-type="table-fn"}
  Regular use of lipid-lowering medication                                                                                     
    No                                                        \-                                                               Ref
    Yes                                                       \-                                                               −5% (−14, 5)
  ***Physical measurements***                                                                                                  
  BMI (kg/m^2^)                                               0.01 (−0.03, 0.05)                                               0% (−1, 2)
  WHR                                                         −0.03 (−0.06, 0.01)                                              −2% (−4, 1)
  SBP (mmHg)                                                  0.01 (−0.03, 0.05)                                               0% (−2, 2)
  DBP (mmHg)                                                  −0.02 (−0.06, 0.02)                                              −1% (−3, 1)
  ***Lipid markers***                                                                                                          
  Total cholesterol (mmol/l)                                  −0.08 (−0.11, 0.04)[\*\*\*](#tf3){ref-type="table-fn"}           −4% (−5, −2)[\*\*\*](#tf3){ref-type="table-fn"}
  HDL-C (mmol/l)                                              −0.04 (−0.08, −0.00)[\*](#tf1){ref-type="table-fn"}              −2% (−4, −0)[\*](#tf1){ref-type="table-fn"}
  Log triglycerides (mmol/l)                                  −0.01 (−0.05, 0.03)                                              −1% (−2, 1)
  ***Metabolic, inflammatory, and renal function markers***                                                                    
  Log hsCRP (mg/l)                                            −0.02 (−0.06, 0.02)                                              −1% (−3, 1)
  Fasting plasma glucose (mmol/l)                             0.03 (−0.01, 0.07)                                               1% (−0, 3)
  Log Creatinine (µmol/l)                                     0.06 (0.02, 0.10)[\*](#tf1){ref-type="table-fn"}                 3% (1, 5)[\*](#tf1){ref-type="table-fn"}
  Cystatine C (mg/dl)                                         0.08 (0.05, 0.12)[\*\*\*](#tf3){ref-type="table-fn"}             4% (2, 6)[\*\*\*](#tf3){ref-type="table-fn"}
  eGFR (ml/min/1.73 m^2^)                                     −0.06 (−0.10, −0.02)[\*\*\*](#tf3){ref-type="table-fn"}          −3% (−5, −1)[\*](#tf1){ref-type="table-fn"}
  Log UAE (mg/24 hours)                                       0.05 (0.01, 0.08)[\*](#tf1){ref-type="table-fn"}                 2% (0, 4)[\*](#tf1){ref-type="table-fn"}

BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; Ref, reference; SD, standard deviation; SBP, systolic blood pressure; UAE, urinary albumin excretion; VCAM-1, vascular cell adhesion molecule-1; WHR, waist-to-hip ratio

Asterisks indicate the level of statistical significance:

*p* \< 0.05

*p* \< 0.01

*p* \< 0.001

Pearson correlation coefficients between loge VCAM-1 and the row variables

Percentage change in VCAM-1 levels per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean VCAM-1 levels for the category versus the reference) adjusted for age and sex;

VCAM-1 Levels and Risk of Incident CVD
--------------------------------------

During a median follow-up of 9.9 (interquartile range, 6.8--10.8) years (22,370 person-years at risk), 614 incident CVD events were recorded. There were 153 stroke outcomes \[subarachnoid hemorrhage (*n* = 9); intracerebral hemorrhage (*n* = 20); other and unspecified intracranial hemorrhage (*n* = 6); occlusion and stenosis of precerebral or cerebral arteries (*n* = 107); and carotid obstruction (*n* = 11)\] and 388 CHD outcomes \[fatal or nonfatal MI (*n* = 155); fatal or nonfatal IHD (*n* = 119); CABG (*n* = 51); and PTCA (*n* = 63)\].

A near log-linear inverse relationship was observed between VCAM-1 levels and CVD risk in analyses adjusted for established CVD risk factors (**[Fig. 1](#F1){ref-type="fig"}**). **[Table 3](#T3){ref-type="table"}** shows the associations of VCAM-1 with cardiovascular outcomes. The HR for CVD per 1 SD increase in log~e~ VCAM-1 was (0.91; 95% CI, 0.85--0.99; *P* = 0.032) in age- and sex-adjusted analyses, which remained consistent in further analyses adjusted for established cardiovascular factors (0.91; 95% CI, 0.84--0.99; *P* = 0.020) and additional adjustment for BMI, alcohol consumption, glucose, log~e~ triglycerides, eGFR, and log~e~ hsCRP (0.89; 95% CI: 0.82--0.97; *P* = 0.006). The association persisted in a final model adjusted for log~e~ UAE (0.88; 95% CI: 0.81--0.95; *P* = 0.002). Alternatively, comparing the top versus bottom quintiles of VCAM-1 levels in similar models, the corresponding adjusted HRs were (0.76; 95% CI: 0.59--0.99; *P* = 0.039), (0.74; 95% CI: 0.57--0.96; *P* = 0.023), (0.70; 95% CI: 0.54--0.91; *P* = 0.007), and (0.66; 95% CI: 0.51--0.86; *P* = 0.002) respectively. HRs were similar in analyses that excluded the first two years of follow-up, participants on regular antihypertensive medication, and participants on regular lipid-lowering medication (**[Table 4](#T4){ref-type="table"}**). The associations did not vary significantly by levels or categories of several clinically relevant individual characteristics (**[Fig. 2](#F2){ref-type="fig"}**). In separate analyses for other cardiovascular outcomes, an inverse association was also demonstrated for CHD in analyses adjusted for several established risk factors and potential confounders; however, for stroke, the initial null association observed in analyses adjusted for established risk factors and several potential confounders became statistically significant with additional adjustment for log~e~ UAE (**[Table 3](#T3){ref-type="table"}**).

![Hazard ratios for incident cardiovascular disease by quintiles of baseline loge VCAM-1 using floating absolute risks\
A, adjusted for age and sex; B, adjustment as in B plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol](jat-24-804-g001){#F1}

###### Association of baseline VCAM-1 concentrations with cardiovascular disease, coronary heart disease, and stroke

  VCAM-1 concentration (mg/dl)   Events/Total   Model 1               Model 2   Model 3               Model 4                                                           
  ------------------------------ -------------- --------------------- --------- --------------------- ---------- --------------------- ---------- --------------------- ----------
  Cardiovascular disease                                                                                                                                                
                                                                                                                                                                        
  Per 1 SD increase              614/2,638      0.91 (0.85 to 0.99)   0.032     0.91 (0.84 to 0.99)   0.020      0.89 (0.82 to 0.97)   0.006      0.88 (0.81 to 0.95)   0.002
  Q1 (179.5--602.1)              117/528        ref                             ref                              ref                              ref                   
  Q2 (603.3--800.5)              113/528        0.85 (0.66 to 1.11)   0.238     0.83 (0.64 to 1.08)   0.167      0.81 (0.63 to 1.06)   0.123      0.83 (0.64 to 1.08)   0.164
  Q3 (800.6--1024.5)             124/527        0.90 (0.70 to 1.16)   0.429     0.83 (0.65 to 1.07)   0.158      0.79 (0.62 to 1.03)   0.079      0.79 (0.61 to 1.02)   0.072
  Q4 (1024.8--1328.0)            130/528        0.90 (0.70 to 1.16)   0.412     0.88 (0.69 to 1.14)   0.338      0.86 (0.66 to 1.10)   0.230      0.85 (0.66 to 1.10)   0.223
  Q5 (≥ 1328.4)                  130/527        0.76 (0.59 to 0.99)   0.039     0.74 (0.57 to 0.96)   0.023      0.70 (0.54 to 0.91)   0.007      0.66 (0.51 to 0.86)   0.002
  *P*-value for trend                                                 0.092                           0.070                            0.027                            0.008
                                                                                                                                                                        
  Coronary heart disease                                                                                                                                                
                                                                                                                                                                        
  Per 1 SD increase              388/2,638      0.86 (0.78 to 0.95)   0.002     0.85 (0.76 to 0.94)   0.001      0.84 (0.76 to 0.92)   0.001      0.82 (0.75 to 0.91)   \< 0.001
  Q1 (179.5--602.1)              82/528         ref                             ref                              ref                              ref                   
  Q2 (603.3--800.5)              67/528         0.71 (0.51 to 0.98)   0.038     0.70 (0.50 to 0.97)   0.030      0.68 (0.49 to 0.95)   0.022      0.70 (0.50 to 0.97)   0.031
  Q3 (800.6--1024.5)             86/527         0.90 (0.66 to 1.21)   0.474     0.81 (0.60 to 1.10)   0.177      0.78 (0.57 to 1.06)   0.111      0.77 (0.57 to 1.05)   0.099
  Q4 (1024.8--1328.0)            83/528         0.79 (0.58 to 1.08)   0.138     0.77 (0.56 to 1.05)   0.094      0.75 (0.55 to 1.03)   0.076      0.76 (0.56 to 1.04)   0.085
  Q5 (≥ 1328.4)                  70/527         0.58 (0.42 to 0.80)   0.001     0.55 (0.40 to 0.77)   \< 0.001   0.53 (0.38 to 0.74)   \< 0.001   0.50 (0.36 to 0.70)   \< 0.001
  *P*-value for trend                                                 0.008                           0.004                            0.002                            0.001
                                                                                                                                                                        
  Stroke                                                                                                                                                                
                                                                                                                                                                        
  Per 1 SD increase              153/2,638      0.88 (0.75 to 1.04)   0.133     0.86 (0.73 to 1.02)   0.078      0.86 (0.73 to 1.01)   0.062      0.83 (0.71 to 0.98)   0.028
  Q1 (179.5--602.1)              31/528         ref                             ref                              ref                              ref                   
  Q2 (603.3--800.5)              31/528         0.93 (0.56 to 1.54)   0.779     0.84 (0.51 to 1.39)   0.490      0.83 (0.50 to 1.37)   0.458      0.84 (0.51 to 1.40)   0.510
  Q3 (800.6--1024.5)             27/527         0.79 (0.47 to 1.32)   0.364     0.75 (0.44 to 1.26)   0.269      0.73 (0.43 to 1.23)   0.240      0.70 (0.41 to 1.18)   0.176
  Q4 (1024.8--1328.0)            34/528         0.90 (0.55 to 1.47)   0.671     0.84 (0.51 to 1.39)   0.502      0.84 (0.51 to 1.38)   0.482      0.82 (0.49 to 1.35)   0.429
  Q5 (≥ 1328.4)                  30/527         0.73 (0.44 to 1.21)   0.224     0.66 (0.39 to 1.11)   0.116      0.63 (0.37 to 1.07)   0.086      0.59 (0.35 to 1.00)   0.051
  *P*-value for trend                                                 0.252                           0.167                            0.135                            0.074

CI, confidence interval; HR, hazard ratio; Q, quintile; SD, standard deviation; VCAM-1, vascular cell adhesion molecule-1

Model 1: Age and sex

Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol

Model 3: Model 2 plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge high sensitivity C-reactive protein

Model 4: Model 3 plus loge urinary albumin excretion

###### Hazard ratios for cardiovascular disease with first two years of follow-up, participants on regular antihypertensive medication, and participants on regular lipid-lowering medication excluded

                                                                  Events/Total   Model 1               Model 2   Model 3               Model 4                                                       
  --------------------------------------------------------------- -------------- --------------------- --------- --------------------- --------- --------------------- ------- --------------------- -------
  Excluding first two years of follow-up                          496/2,446      0.91 (0.84 to 1.00)   0.036     0.90 (0.82 to 0.98)   0.020     0.88 (0.81 to 0.97)   0.008   0.87 (0.79 to 0.95)   0.002
                                                                                                                                                                                                     
  Excluding participants on regular antihypertensive medication   447/2,281      0.90 (0.82 to 1.00)   0.044     0.90 (0.82 to 0.99)   0.036     0.88 (0.80 to 0.97)   0.013   0.88 (0.80 to 0.97)   0.013
                                                                                                                                                                                                     
  Excluding participants on regular lipid-lowering medication     566/2,550      0.92 (0.85 to 1.00)   0.053     0.91 (0.84 to 1.00)   0.035     0.90 (0.83 to 0.98)   0.015   0.88 (0.81 to 0.96)   0.004

Hazard ratios are reported per 1 standard deviation increase in loge VCAM-1 levels; CI, confidence interval

Model 1: Age and sex

Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol

Model 3: Model 2 plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge high sensitivity C-reactive protein

Model 4: Model 3 plus loge urinary albumin excretion

![Hazard ratios for cardiovascular disease, by several participant level characteristics\
Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol; CI, confidence interval (bars); CVD, cardiovascular disease; Estimated GFR, glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high sensitivity C-reactive protein; SD, standard deviation; UAE, urinary albumin excretion; \*, *P*-value for interaction; cut-offs used for fasting glucose, body mass index, systolic blood pressure, total cholesterol, HDL-C, triglycerides, estimated GFR, and hsCRP are median values.](jat-24-804-g002){#F2}

VCAM-1 and CVD Risk Prediction
------------------------------

A CVD risk prediction model containing risk factors based on the Framingham CVD Risk Score yielded a C-index of 0.7590 (95% CI: 0.7404--0.7776). After addition of information on VCAM-1 levels, the C-index was 0.7596 (0.7410 to 0.7783), representing a non-significant increase of 0.0006 (−0.0014 to 0.0026; *P* = 0.543). There was no improvement in the classification of participants into predicted 10-year CVD risk categories (NRI: 0.00%, −0.41% to 1.42%; *P* = 0.996).

Discussion
==========

Summary of Main Findings
------------------------

In this population-based study of individuals without a history of CVD at baseline, baseline VCAM-1 levels were weakly correlated with several cardiovascular risk markers. In analyses adjusted for established CVD risk factors, we observed an inverse near linear association of VCAM-1 with risk of CVD. The association remained consistent on further adjustment for several potential confounders, including UAE. The findings were consistent across several clinically relevant subgroups and levels of cardiovascular risk markers. The associations were similar in several sensitivity analyses. Similar inverse associations were observed for CHD risk. There was no statistically significant evidence of an association with stroke in analyses adjusted for established risk factors and several potential confounders; however, further adjustment for UAE strengthened the association due to a negative confounding effect of UAE on the association. This was unexpected given the positive correlation of VCAM-1 with UAE and the knowledge that albuminuria is a putative marker for endothelial dysfunction and is independently associated with increased vascular risk^[@bib47])^. Indeed, further exploration of the current data showed a positive and independent association between UAE and stroke risk. Findings from the assessments of improvements in measures of risk discrimination and reclassification indicate that additional information on VCAM-1 measurements provides no significant improvement in CVD risk prediction.

Comparison with Previous Work
-----------------------------

To our knowledge, this is the first study to assess the association between VCAM-1 and the composite outcome of CVD and to report inverse associations between VCAM-1 and the outcomes of CVD, CHD, and stroke. Previous studies conducted on the topic have mostly reported no evidence of any associations of VCAM-1 with cardiovascular outcomes. In analysis of the British Regional Heart Study cohort, Malik and colleagues demonstrated no statistically significant evidence of an association of VCAM-1 with CHD^[@bib25])^. In addition, they conducted a pooled analysis of four studies (including their study), but this did not change the null findings. Luc and colleagues found no evidence of an association between VCAM-1 and the risk of acute coronary events in their analysis of the Epidemiological Study of Myocardial Infarction Study (PRIME), which enrolled apparently healthy men aged 50--59 years at baseline^[@bib21])^. Similarly, no statistically significant evidence of an association was found between VCAM-1 and CHD risk in the Health Professional Follow-up Study^[@bib48])^. On the contrary, Jager and colleagues, in a 7.4 year follow-up of the Hoorn study of 631 participants, demonstrated elevated VCAM-1 levels to be independently associated with cardiovascular mortality in subjects with type 2 diabetes^[@bib26])^. However, a subset of study participants (24%) had a history of CVD at baseline, and though the study authors accounted for this in their models, stratified analysis by history of CVD was not conducted. In our study, stratified analysis by history of diabetes showed no statistically significant evidence of effect modification. A protective effect of VCAM-1 on CVD risk was observed for participants without a history of diabetes, but the results were not statistically significant for participants with a history of diabetes. Given the small sample and low event rate for this subgroup, the null results could be attributed to low power; however, a trend towards a protective effect was observed.

Possible Explanations for Findings
----------------------------------

Our findings would suggest that higher circulating concentrations of VCAM-1 are protective of cardiovascular outcomes. There was however no statistically significant evidence of an association of VCAM-1 with the specific outcome of stroke, which could be due to the low event rate. Though previous studies conducted in general population settings have failed to demonstrate any statistically significant association of VCAM-1 with CVD risk, an increased risk of CVD with elevated levels of VCAM-1 has been suggested, given that circulating levels of other soluble adhesion molecules (such as E-selectin, P-selectin, or ICAM-1) have been found to be positively and independently associated with CVD outcomes^[@bib16],\ [@bib19]--[@bib24])^. Indeed, the therapeutic effect of leech enzyme extract on atherosclerosis (a traditional Chinese medicine commonly used for treating CVD) has been shown to be manifested via inhibiting the expression of adhesion molecules such as ICAM-1 and VCAM-1^[@bib49])^. The mechanistic pathways for the link between elevated VCAM-1 levels and its protective effect on the development of CVD are unclear, as increased expression of soluble adhesion molecules have been suggested to play a direct role in the pathogenesis of atherosclerosis^[@bib50])^ via endothelial dysfunction and inflammation. These observations may reflect the differences in the functions of these adhesion molecules and suggest that there may be important pathophysiologic differences between these molecules and the genesis of atherosclerosis. E-selectin is expressed exclusively by endothelial cells and therefore may be a better marker of endothelial dysfunction, whereas ICAM-1 and VCAM-1 are expressed on a number of cells, including endothelial cells and leukocytes^[@bib51])^. Whiles E-selectin and P-selectin mediate transient rolling of leucocytes along the endothelium^[@bib11])^, ICAM-1 and VCAM-1 allow stronger leukocyte rolling and attachment to the endothelium^[@bib9])^. Intercellular adhesion molecule-1, which has been consistently demonstrated to be associated with incident vascular events, is highly expressed by endothelial cells in human atheroma, and low levels have been expressed on normal endothelium. In contrast, VCAM-1 is not expressed at all on normal endothelium, and lower levels of expression have been found in human atheroma^[@bib14],\ [@bib52])^. A previous study has also suggested that ICAM-1 and VCAM-1 function at opposite ends of the atherosclerosis spectrum and that their interaction with CVD involves a more complex process^[@bib48])^. There is also a possibility that the null associations demonstrated in previous studies may be attributable to study design and participant characteristics such as sample size, duration of follow-up, and age and sex of participants. Compared to some previous studies^[@bib21],\ [@bib48],\ [@bib53])^, our study had a longer follow-up and a higher event rate. Given the postulated role of VCAM-1 in the early atherosclerotic process^[@bib54],\ [@bib55])^, longer follow-up durations may be needed to demonstrate any association that we demonstrated in our study. In addition, the majority of previous studies have demonstrated these null associations in cohorts only limited to men, whereas the current study involved both men and women^[@bib21],\ [@bib48],\ [@bib56])^. Indeed, our subgroup analyses showed no statistically significant associations in both genders, though there were trends towards protective associations. Finally, while our cohort involved relatively younger to older participants, previous studies employed middle-aged to elderly participants in their samples^[@bib21],\ [@bib48],\ [@bib56])^. These explanations and mechanisms are however speculative and further work is warranted to identify key underlying biological mechanisms through which VCAM-1 may play a protective role in the development of CVD.

Implications of Findings
------------------------

The findings of our study may have clinical implications. Irrespective of the irrelevance of the utility of VCAM-1 in CVD risk prediction, its use for CVD risk prevention and treatment may still have relevance. The overall evidence supports the possibility that elevated VCAM-1 levels might protect from CVD events in the general population. It highlights the vascular endothelium as a potential therapeutic target for the prevention and/or treatment of CVD. Circulating VCAM-1 levels may be a potential biomarker for monitoring the effects of treatment on the vascular endothelium. Nonetheless, given that this is the first study to demonstrate these findings; further studies are needed to replicate these findings.

Strengths and Limitations
-------------------------

This is the first simultaneous and comprehensive assessment of the association of VCAM-1 with the risk of incident composite CVD, CHD, and stroke. Other strengths include the nationally representative sample, the large endpoint numbers by most standards, the high response and long-term follow-up, and measurements on a comprehensive panel of lifestyle and biological markers that permitted adequate adjustment for potential confounders. Reverse-causation bias was minimized as individuals with prevalent CVD at baseline were excluded from the analyses at the onset. The analyses were detailed, which included comparison of the associations at different levels or categories of vascular risk markers, several sensitivity analyses to supplement and contextualize the principal findings, and risk prediction analyses. Limitations include the potential for residual confounding due to errors in measurements of risk marker and other unmeasured confounders; absence of repeat measurements of VCAM-1 which precluded the ability to correct for regression dilution bias, which could have underestimated the association between long-term VCAM-1 levels and CVD; and analyses which were based on a predominantly white-European population, therefore the findings may not be generalizable to individuals of different ethnicities. In addition, blood samples for VCAM-1 measurements involved long-term storage which could have resulted in under-estimation of the associations due to sample degradation. However, it has been reported that VCAM-1 is not known to be influenced by repeated freeze-thaw cycles after storage^[@bib57])^.

In conclusion, available evidence for the first time shows that VCAM-1 is protective of incident CVD. Addition of information on VCAM-1 to conventional risk factors provides no significant improvement in CVD risk prediction in the general population. Further studies are needed to replicate this association and the etiological mechanisms underlying these data require investigation.
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